What is Nouscom?
Nouscom is at the forefront of developing engineered viral vectored vaccines and oncolytic viruses for cancer treatment. The company leverages proprietary platforms to design cancer vaccines capable of encoding multiple tumor neoantigens, thereby amplifying the immune system's response against malignant cells. With operational bases in Basel, Switzerland, and Rome, Italy, Nouscom is dedicated to advancing both off-the-shelf and personalized immunotherapies across a spectrum of cancer types, aiming to significantly improve patient outcomes.
How much funding has Nouscom raised?
Nouscom has raised a total of $142.2M across 3 funding rounds:
Series A
$13.6M
Series B
$46.6M
Series C
$82M
Series A (2016): $13.6M with participation from Versant Ventures and LSP Ventures
Series B (2017): $46.6M led by Abingworth, 5AM Ventures, Versant Ventures, and Life Sciences Partners
Series C (2024): $82M supported by Andera Partners, X-Gen Ventures, Revelation Partners, Bpifrance, and Angelini Ventures
Key Investors in Nouscom
Andera Partners
Andera Partners is a major player in private company investments, with a dedicated life sciences team that brings extensive experience in the industry, private equity, and venture capital. They invest in biotech and medtech companies, supporting innovation from their European base.
X-Gen Ventures
X-Gen Ventures operates within the Information & Document Management industry, indicating a potential interest in companies that leverage data and technology for therapeutic development or operational efficiency.
Revelation Partners
Revelation Law Partners is a legal firm specializing in financial and corporate matters, suggesting an interest in companies with strong financial structures and strategic growth plans, particularly within the life sciences sector.
What's next for Nouscom?
The substantial enterprise-level funding, including the recent major strategic investment, positions Nouscom for accelerated growth and the advancement of its pipeline. This capital infusion is expected to fuel further research and development, clinical trials, and the scaling of its manufacturing capabilities. The company's focus on novel immunotherapies suggests a strategic push towards bringing its promising treatments to market, potentially marking a new era in cancer care.
See full Nouscom company page
